Loading...
The MOSAIC trial (J Clin Oncol 2009 27:3109) and the NSABP C-07 trial (JW Oncol Hematol Jul 2 2007) showed that adding oxaliplatin to infusional or bolus 5-fluorouracil (FU) and folinic acid (FA) adjuvant therapy improved disease-free survival (DFS) in patients with advanced colon cancer.
Now, to determine the efficacy and safety of adding oxaliplatin to the oral fluoropyrimidine capecitabine in the setting of postoperative chemotherapy, investigators conducted an industry-supported, randomized, phase III trial involving 1886 adults with stage III disease from 226 medical centers in 29 countries. Patients received adjuvant therapy with either intravenous FU/FA using the Mayo Clinic (MC) or Roswell Park (RP) schedule or XELOX (oxaliplatin 130…